BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-4.07%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$8.61B
AUM Growth
+$8.61B
(-11%)
Cap. Flow
-$378M
Cap. Flow
% of AUM
-4.39%
Top 10 Holdings %
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30
Top Buys
| 1 |
Outset Medical
OM
|
$66.1M |
| 2 |
Boston Scientific
BSX
|
$42.1M |
| 3 |
CareDx
CDNA
|
$31.2M |
| 4 |
Pacific Biosciences
PACB
|
$30.3M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
$29.8M |
Top Sells
| 1 |
Biogen
BIIB
|
$106M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$81.3M |
| 3 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
$75.3M |
| 4 |
Danaher
DHR
|
$68.9M |
| 5 |
Humana
HUM
|
$68M |
Sector Composition
| 1 | Healthcare | 98.39% |
| 2 | Industrials | 0.69% |
| 3 | Energy | 0.03% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACCD
51
DELISTED
Accolade, Inc. Common Stock
ACCD
| $59.4M | 0.69% |
3,381,507
+660,132
| +24% | +$11.6M |
|
52
CRISPR Therapeutics
CRSP
$4.82B
| $58.2M | 0.68% |
926,905
-47,779
| -5% | -$3M |
|
53
Apellis Pharmaceuticals
APLS
$3.51B
| $55.8M | 0.65% |
1,098,712
+448,121
| +69% | +$22.8M |
|
54
Centene
CNC
$14.8B
| $55.6M | 0.65% |
660,635
+625
| +0.1% | +$52.6K |
|
55
Globus Medical
GMED
$7.94B
| $55M | 0.64% |
745,254
-12,210
| -2% | -$901K |
|
56
AbbVie
ABBV
$374B
| $50.5M | 0.59% |
311,500
+4,600
| +1% | +$746K |
|
57
Exact Sciences
EXAS
$9.33B
| $50.3M | 0.58% |
719,303
+76,721
| +12% | +$5.36M |
|
|
ABMD
58
DELISTED
Abiomed Inc
ABMD
| $49.7M | 0.58% |
150,178
| – | – |
|
59
Omnicell
OMCL
$1.51B
| $46.9M | 0.54% |
362,332
| – | – |
|
60
Bristol-Myers Squibb
BMY
$96.7B
| $45.9M | 0.53% |
628,128
-431,219
| -41% | -$31.5M |
|
|
61
Pacific Biosciences
PACB
$378M
| $44.4M | 0.52% |
4,881,752
+3,328,729
| +214% | +$30.3M |
|
62
Adaptive Biotechnologies
ADPT
$1.96B
| $43.7M | 0.51% |
3,145,293
+1,176,862
| +60% | +$16.3M |
|
|
SILK
63
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $43.2M | 0.5% |
1,045,567
+93,134
| +10% | +$3.85M |
|
64
Penumbra
PEN
$10.5B
| $43M | 0.5% |
193,654
-80
| -0% | -$17.8K |
|
65
Thermo Fisher Scientific
TMO
$183B
| $42.9M | 0.5% |
72,633
-25,695
| -26% | -$15.2M |
|
66
Halozyme
HALO
$8.75B
| $40.8M | 0.47% |
1,024,200
-43,300
| -4% | -$1.73M |
|
67
Bio-Rad Laboratories Class A
BIO
$7.8B
| $40.6M | 0.47% |
72,009
+32,326
| +81% | +$18.2M |
|
68
AtriCure
ATRC
$1.73B
| $39.3M | 0.46% |
598,605
+100,049
| +20% | +$6.57M |
|
|
MTEM
69
DELISTED
Molecular Templates, Inc.
MTEM
| $38.2M | 0.44% |
738,534
+13,334
| +2% | +$690K |
|
70
Baxter International
BAX
$12.1B
| $38M | 0.44% |
489,880
+40,031
| +9% | +$3.1M |
|
71
IQVIA
IQV
$31.4B
| $36.8M | 0.43% |
159,120
-4,400
| -3% | -$1.02M |
|
|
HZNP
72
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $36.3M | 0.42% |
345,100
-23,500
| -6% | -$2.47M |
|
73
Charles River Laboratories
CRL
$7.99B
| $35.9M | 0.42% |
126,406
+60,495
| +92% | +$17.2M |
|
74
Cooper Companies
COO
$13.3B
| $34.8M | 0.4% |
332,864
-412
| -0.1% | -$43K |
|
75
Teleflex
TFX
$5.57B
| $34.7M | 0.4% |
97,714
-57
| -0.1% | -$20.2K |
|